Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.22% to $8.78 Tuesday, on what proved to be an all-around mixed ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study of ...

The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors ( Perez, ...

H.C. Wainwright analyst Andres Y. Maldonado confirmed a Buy rating and a $75.00 price target on Corbus Pharmaceuticals (NASDAQ:CRBP), representing significant upside potential from the current price ...

The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

Asia Pacific Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, ...

North America pharmaceutical manufacturing industry market is projected to grow by 8.3% annually in the forecast period and reach $9.08 million by 2032. The growth is driven by the increased drug ...

Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings ... NY Dr. Cohen will participate in analyst led fireside discussion and will attend one-on-one investor meetings.